

This report has been issued for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of third parties regarding revenues, earnings and business developments. Such estimates and forecasts cannot be independently verified by reason of the subjective character. CPH Chemie + Papier Holding AG gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.

This report is not a prospectus within the meaning of art. 652a CO or art. 27 et seq. of the SIX Listing Rules. This document is neither an advice on investment, nor a recommendation or invitation for purchasing, holding or selling any securities, money market instruments or derivatives and no investment decision should be based on this report. This report speaks as of its date. Neither CPH Chemie + Papier Holding AG nor Dynamics Group AG assume any responsibility to up-date the report.

CPH Chemie + Papier Holding AG

Switzerland | Industrial Goods & Services

Event update


03 November 2017

Company Data

Price:	CHF 56.50
Market Cap:	CHF 339.0mn
Free Float:	41.7%
No. of shares:	6.0mn
Avg. traded volume (1 year):	1,086.8
Bloomberg:	CPHN SW
Reuters:	CPHN-EB
ISIN:	CH0001624717

Source: SIX Swiss Exchange and Bloomberg

Share Price Development



Source: Bloomberg

Key Financial Data

	2015	2016	2017E	2018E
Sales	420.0	434.8	458.1	477.6
EBITDA %	2.9%	8.5%	6.9%	8.8%
EBIT %	(5.2%)	1.4%	0.0%	2.1%
Net Margin %	(7.9%)	(1.8%)	0.3%	0.8%
Basic EPS	(5.52)	(1.32)	0.20	0.61
Diluted EPS	(5.52)	(1.32)	0.20	0.61
DPS	0.60	0.65	0.65	0.65
Equity Ratio %	64.5%	56.2%	56.4%	56.8%
Net capex	(22.0)	(1.5)	(36.5)	(21.4)
P/Sales	0.6x	0.8x	0.7x	0.7x
P/E	NM	NM	NM	92.08x
EV/EBITDA	25.8x	11.2x	13.2x	9.9x

Next Events

Annual Results Conference	20 Feb 2018
Ordinary General Meeting	14 Mar 2018
Half-Year Results	July 2018

Analysts

Doris Rudischhauser
dru@researchdynamics.ch

Alexandre Müller
amu@researchdynamics.ch

Tel: +41 43 268 3232

www.researchdynamics.ch

CPH strengthens its chemicals' position

CPH Chemie + Paper Holding AG (CPH/the group) is a diversified industrial group with activities in the paper, chemical products and pharmaceutical packaging films industries. CPH generates around 55% of its revenues from the Paper division, where almost all sales come from Europe. CPH is one of the only two newsprint paper producers in the Swiss market and the country's sole magazine paper producer. The Packaging division manufactures high barrier films for the global pharmaceutical industry and is the third-largest supplier of PVC coated high-barrier films. The Chemistry division produces molecular sieves and has a global exposure.

Armar AG will be integrated in CPH's Chemistry Division

CPH's Chemistry division, Zeochem AG, will acquire its long-term and established distribution partner Armar AG. The acquisition, which is effective from 1 March 2018, will help the smallest of CPH's divisions to expand its business in deuterated solvents. These are used as synthetic building blocks in pharmaceutical agents, in NMR spectroscopy and for the production of organic light-emitting diodes or OLEDs. The transaction was facilitated by a succession situation since the shareholder and CEO of the company, Adrian Geiger, was looking to transfer his stake. He will also move to Zeochem with the transfer of the business. According to the agreement, Zeochem AG would integrate Armar's current production at its operational unit in Rüti (Canton Zurich).

We assume that, geographically, most customers of Armar are situated in Europe and – given the existing distribution relationship – there should be no major overlap with Zeochem's customers. Thus, the transaction should be fully complementary on the customer and product portfolios and marks a further move by CPH to diversify its revenue base away from its largest, the Paper, division into more growth-oriented industries such as Chemicals and/or Packaging.

In terms of financials, CPH indicated that the annual revenue of Armar would be in the mid-single digit million range (for modelling purposes we assume ~CHF 5 million), with an estimated 2018E contribution of CHF4 million-CHF4.5 million to CPH's top-line. We believe that the EBIT margin of Armar should be broadly in line with CPH's Chemistry division's margin of 5%. Thus, we estimate an accretion of CHF 0.2 million to the 2018E EBIT. We have adjusted our 2018E estimates accordingly and increased our sales and EBIT estimates on a Group level by 0.9% and 2.1%, respectively. Since no further information was disclosed regarding the terms of the transaction, we leave our current balance sheet and cash flow estimates unchanged.

Overall, we are encouraged by the management's move to supplement the Chemistry division's deuterated products portfolio by acquiring and integrating its longstanding distribution partner.

Valuation and conclusion

We value CPH using DCF and relative valuation techniques. In the DCF analysis, we have retained our WACC at 6.1%. Considering the better growth prospects post the acquisition, we increased our target price to CHF60.9 per share from CHF57.2 per share earlier, which gives an upside of 7.8% from the current levels.

On a relative basis, the stock is trading at a steep discount of ~39% to the weighted average of its peers on a 2018E P/S basis. Similarly, the company trades at discount of ~7% on a 2018E EV/EBITDA basis.

We believe, in the medium-term, the stock could trade at higher multiples on account of an increased contribution of sales and operating profits expected out of the non-paper related Chemicals' and Packaging division as well as the Asia-Pacific region. In addition, higher operating efficiencies from new production facilities coupled with acquisition synergies should help to improve the profitability profile in the medium term.

Exhibit 1: CPH – Comparison with division peers

Company	EV/EBITDA			P/S			P/E		
	3 year average	CY2017E	CY2018E	3 year average	CY2017E	CY2018E	3 year average	CY2017E	CY2018E
CPH Chemie & Paper	9.5x	9.8x	9.0x	0.6x	0.6x	0.6x	24.6x	24.6x	34.1x
Paper peers:									
Holmen	11.5x	11.3x	10.7x	1.6x	1.5x	1.3x	29.8x	29.9x	22.5x
Stora Enso	7.1x	6.9x	7.2x	0.7x	0.7x	0.6x	27.9x	33.9x	29.4x
Altri	7.7x	7.7x	7.7x	1.3x	1.2x	1.0x	11.1x	11.2x	10.3x
Metsa Board	12.0x	11.8x	12.4x	1.1x	1.0x	0.8x	20.0x	19.6x	17.0x
UPM-Kymmene	8.6x	8.6x	7.4x	1.0x	0.9x	0.8x	13.5x	13.4x	13.8x
Norsk Skogindustrier	11.4x	11.6x	12.8x	0.0x	0.1x	0.1x	2.9x	2.9x	2.9x
James Cropper	13.0x	12.0x	10.4x	1.0x	0.8x	0.6x	29.4x	28.5x	41.3x
OJI Holdings	10.0x	10.0x	10.0x	0.4x	0.4x	0.3x	32.3x	32.0x	25.0x
Chemistry peers:									
Honeywell Int.	11.2x	10.7x	10.9x	2.2x	2.1x	1.9x	18.9x	18.6x	19.4x
Clariant	9.9x	9.7x	9.3x	1.0x	1.0x	0.9x	26.4x	25.6x	27.8x
Arkema	7.2x	7.1x	7.1x	0.8x	0.8x	0.8x	19.9x	20.0x	19.0x
WR Grace & Co.	18.3x	17.8x	14.5x	2.8x	2.7x	2.2x	39.5x	38.1x	49.2x
Packaging peers:									
Meadwestwaco	10.6x	10.7x	11.1x	1.5x	1.4x	1.2x	27.8x	26.4x	41.4x
MacFarlane Group	9.0x	8.8x	7.8x	0.4x	0.4x	0.3x	13.2x	13.1x	12.1x
Gerresheimer	9.6x	9.5x	8.8x	1.6x	1.5x	1.4x	28.4x	26.3x	25.2x
West Pharmaceutical Services	19.3x	18.5x	15.9x	3.6x	3.3x	2.8x	43.0x	41.9x	36.2x
Convertidora Industrial	7.8x	8.0x	8.3x	0.4x	0.4x	0.4x	36.6x	33.4x	31.6x
PSB Industries	5.9x	5.9x	5.6x	0.6x	0.6x	0.5x	10.9x	10.9x	10.6x
Astrapak Ltd	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bicare Ltd	11.9x	10.8x	8.5x	0.6x	0.1x	0.1x	NA	Na	3.7x
Median	10.0x	10.0x	9.3x	1.0x	0.9x	0.8x	27.1x	25.9x	22.5x
High	19.3x	18.5x	15.9x	3.6x	3.3x	2.8x	43.0x	41.9x	49.2x
Low	5.9x	5.9x	5.6x	0.0x	0.1x	0.1x	2.9x	2.9x	2.9x
Premium (disc) to peers	(5%)	(2%)	(3%)	(43%)	(40%)	(17%)	NA	(5%)	51%

Source: Thomson Eikon (as on 02 Nov 2017)

Exhibit 2: CPH – Comparison with weighted average of division peers

	EV/EBITDA			P/S			P/E		
	3 year average	CY2017E	CY2018E	3 year average	CY2017E	CY2018E	3 year average	CY2017E	CY2018E
Weighted peer multiples	10.3x	10.1x	9.7x	1.2x	1.2x	1.1x	24.6x	24.0x	23.4x
CPH	9.5x	9.8x	9.0x	0.6x	0.6x	0.6x	24.6x	24.6x	34.1x
Premium (disc) to peers	(8%)	(3%)	(7%)	(54%)	(52%)	(39%)	NM	3%	45%

Source: Thomson Eikon (as on 02 Nov 2017)

DETAILED FINANCIAL STATEMENTS

Income Statement

CHF mn (except per share)	FY12	FY13	FY14	FY15	FY16	FY17E	FY18E
Chemistry sales	68	59	60	63	69	76	85
Paper sales	314	306	314	248	246	257	259
Packaging sales	106	116	118	110	119	126	133
Net Sales	489	481	492	420	435	458	478
Cost of Sales	(325)	(323)	(313)	(285)	(267)	(289)	(296)
Gross profit	163	158	180	135	168	169	182
Personnel cost	(85)	(86)	(88)	(86)	(89)	(94)	(96)
Outsourced maintenance/repairs	(19)	(19)	(18)	(16)	(18)	(18)	(19)
Other operating expense	(21)	(22)	(23)	(21)	(25)	(25)	(25)
Total operating costs	(125)	(127)	(129)	(123)	(131)	(137)	(140)
EBITDA	38	31	51	12	37	31	42
Depreciation on tangible fixed assets	(59)	(57)	(34)	(34)	(31)	(31)	(31)
Depreciation on intangible assets	(2)	(1)	(1)	(0)	(1)	(1)	(1)
Operating profit (EBIT) before impairment	(22)	(27)	16	(22)	6	0	10
Impairment	0	(251)	0	0	0	0	0
Operating profit (EBIT)	(22)	(278)	16	(22)	6	0	10
Finance costs	(7)	(5)	(7)	(13)	(6)	(6)	(6)
Finance income	1	1	2	1	1	0	0
Total financial income (expenses)	(6)	(4)	(6)	(12)	(5)	(6)	(6)
Profit before taxes (before exceptional items)	(28)	(281)	10	(34)	1	(6)	4
Non-operating items	38	2	1	2	(4)	10	0
Income taxes	(2)	8	(1)	(1)	(4)	(3)	(0)
Profit attributable to the parent	8	(271)	11	(33)	(8)	1	4
Basic EPS	1.3	(45.2)	1.8	(5.5)	(1.3)	0.2	0.6
Diluted EPS	1.3	(45.2)	1.8	(5.5)	(1.3)	0.2	0.6
DPS	0.7	0.7	0.7	0.6	0.7	0.6	0.6

Source: Research Dynamics, Company data

Balance Sheet

CHF mn	FY12	FY13	FY14	FY15	FY16	FY17E	FY18E
Assets							
Non-current assets							
PPE	719.7	433.7	419.1	404.3	384.6	388.8	377.1
Intangible assets	1.5	1.2	1.3	2.4	3.1	4.0	5.1
Long-term financial assets	10.0	10.0	10.0	10.0	10.0	10.0	10.0
Long-term financial receivables	0.0	0.0	2.8	0.0	0.0	0.0	0.0
Other non-current assets	21.2	22.4	22.7	20.2	52.6	52.6	52.6
Total non-current Assets	752.4	467.3	456.0	436.9	450.3	455.4	444.9
Current assets							
Inventories	58.8	56.9	63.4	54.5	68.9	61.6	61.6
Trade accounts receivable	74.0	70.8	79.5	66.4	69.1	69.0	72.0
Other receivables	10.7	7.3	7.7	8.0	8.9	8.9	8.9
Prepaid expenses and accrued income	3.0	5.3	6.6	4.9	4.8	4.8	4.8
Short-term financial receivables	0.2	0.0	0.1	0.0	0.1	0.1	0.1
Liquid funds and Securities	73.3	74.2	75.1	53.2	70.4	65.4	68.2
Total assets	972.4	681.8	688.4	624.0	672.4	665.3	660.5
Shareholders' Equity and Liabilities							
Share capital	30.0	30.0	30.0	30.0	30.0	30.0	30.0
Capital reserves	20.1	16.2	12.3	8.4	4.8	0.9	(3.0)
Profit reserves	651.6	659.5	389.2	397.4	351.2	343.3	344.5
Net result for the year	8.1	(271.5)	10.5	(33.1)	(7.9)	1.2	3.7
Non-current liabilities							
Long-term financial liabilities	144.0	117.9	128.0	126.5	145.6	129.2	125.8
Pension scheme liabilities	0.5	0.7	0.6	1.0	1.1	1.1	1.1
Other long-term liabilities	0.0	2.5	2.4	2.3	0.1	0.1	0.1
Long-term provisions	31.3	21.3	20.8	20.0	52.5	52.5	52.5
Current liabilities							
Trade accounts payable	52.9	59.4	53.8	46.7	53.1	55.3	54.8
Other payables	2.6	4.4	3.9	2.6	8.3	8.3	8.3
Accrued liabilities and deferred income	15.8	11.0	9.1	13.6	16.5	16.5	16.5
Short-term financial liabilities	9.8	23.0	22.6	6.8	7.0	23.3	22.7
Short-term provisions	5.7	7.2	5.1	1.5	7.6	0.9	0.9
Total liabilities	262.6	247.5	246.4	221.2	291.6	287.2	282.6
Total equity and liab.	972.4	681.8	688.4	624.0	672.4	665.3	660.5

Source: Research Dynamics, Company data

Cash Flow Statement

CHF mn	FY12	FY13	FY14	FY15	FY16	FY17E	FY18E
Net profit for the period	8.1	(271.5)	10.5	(33.1)	(7.7)	1.2	3.7
Non-cash adjustments:	20.8	298.8	30.3	35.3	33.9	31.4	31.9
Change in CA and CL:							
(Increase)/ decrease in inventories	(1.7)	(2.6)	(5.5)	8.4	(13.1)	7.3	0.1
Decrease in trade accounts receivable	1.3	3.4	(11.2)	8.1	(0.5)	0.0	(2.9)
Increase/ (decrease) in trade accounts payable	13.0	6.4	(5.8)	(6.8)	1.6	2.3	(0.6)
Other changes in working capital	0.8	(3.0)	1.5	6.5	5.6	(6.7)	-
Cash flows from operating activities	42.3	31.4	19.8	23.3	21.9	35.5	32.2
Investments in tangible fixed assets	(10.9)	(18.2)	(19.2)	(21.9)	(20.7)	(35.0)	(19.4)
Disposals of tangible fixed assets	30.1	0.9	0.4	1.6	20.5	-	-
Investments in intangible assets	(0.3)	(0.5)	(0.6)	(1.6)	(1.2)	(1.5)	(2.0)
Sale of subsidiary/ Divestiture of interests	-	-	-	-	-	-	-
Repayment of long-term financial receivables	2.5	0.0	-	-	-	-	-
Cash flow generated (used) in investment act.	21.4	(17.8)	(19.4)	(22.0)	(19.9)	(36.5)	(21.4)
Increase/ (Decrease) in short-term financial liabilities and receivables	(1.5)	(2.0)	(0.4)	(15.3)	0.1	16.3	(0.6)
Increase/ (Decrease) in long-term financial liabilities	(25.1)	(10.8)	9.8	(1.1)	19.0	(16.3)	(3.4)
Increase in other long-term liabilities	0.0	2.5	(0.2)	(0.1)	(0.4)	-	-
Minority interests and changes resulting from minorities	-	-	-	-	-	-	-
Dividends to shareholders	(3.9)	(3.9)	(3.9)	(3.9)	(3.6)	(3.9)	(3.9)
Cash flow generated (used) in financing act.	(30.6)	(14.2)	5.3	(20.4)	15.2	(3.9)	(7.9)
Exchange (losses)/gains	0.1	(0.2)	0.2	2.3	0.1	-	-
Net change in cash	33.2	(0.7)	6.0	(16.7)	17.2	(4.9)	2.8
Opening cash balance	31.5	64.7	63.9	69.9	53.1	70.3	65.4
Closing cash balance	64.7	63.9	69.9	53.1	70.3	65.4	68.2

Source: Research Dynamics, Company data

Key Ratios

	FY12	FY13	FY14	FY15	FY16	FY17E	FY18E
Growth Ratios							
Sales Growth	(6%)	(2%)	2%	(15%)	4%	5%	4%
Chemistry division	(33%)	(13%)	2%	4%	11%	9%	13%
Paper division	(0%)	(3%)	3%	(21%)	(1%)	4%	1%
Packaging division	1%	9%	1%	(7%)	9%	5%	6%
Operating Profit Growth	NM	NM	NM	NM	NM	(99%)	NM
Net Income Growth	NM	NM	NM	NM	NM	NM	213%
Profitability Ratios (%)							
Operating margin (before impairment) (%)	(5%)	(6%)	3%	(5%)	1%	0%	2%
Chemistry division	(0%)	(9%)	(4%)	(3%)	2%	5%	5%
Paper division	(8%)	(10%)	4%	(11%)	(2%)	(5%)	(1%)
Packaging division	5%	6%	4%	5%	8%	8%	8%
EBITDA Margin %	8%	6%	10%	3%	8%	7%	9%
Net Margin (%)	2%	(56%)	2%	(8%)	(2%)	0%	1%
Return Ratios							
Profit Margin	2%	(56%)	2%	(8%)	(2%)	0%	1%
Asset Turnover	0.5x	0.6x	0.7x	0.6x	0.7x	0.7x	0.7x
Financial Leverage	1.4x	1.4x	1.6x	1.6x	1.7x	1.8x	1.8x
Dupont ROE (%)	1%	(47%)	2%	(8%)	(2%)	0%	1%
ROCE (%)	(3%)	(5%)	3%	(4%)	1%	0%	2%
ROA (%)	1%	(33%)	2%	(5%)	(1%)	0%	1%
Leverage Ratios							
Debt - Equity Ratio	0.2x	0.3x	0.3x	0.3x	0.4x	0.4x	0.4x
Net Debt - Equity Ratio	0.1x	0.2x	0.2x	0.2x	0.2x	0.2x	0.2x
Interest Coverage	(3.2x)	(6.0x)	5.2x	(5.5x)	1.4x	0.0x	1.7x
Liquidity Ratios							
Current Ratio	2.5x	2.0x	2.5x	2.6x	2.4x	2.0x	2.1x
Quick Ratio	1.9x	1.5x	1.8x	1.9x	1.7x	1.4x	1.5x
Valuation Ratios							
EV/EBITDA	12.3x	13.7x	6.2x	25.8x	11.2x	13.2x	9.9x
P/E	48.4x	NM	22.9x	NM	NM	288.0x	92.1x
P/BV	0.5x	0.8x	0.5x	0.6x	0.9x	0.9x	0.9x

Source: Research Dynamics, Bloomberg, Company data

DISCLAIMER

CPH Chemie + Papier Holding AG ("CPH") is a client of Research Dynamics. The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. Research Dynamics is a division of Dynamics Group AG. Dynamics Group is an independent consultancy firm focused on strategic advisory, communication management and research and analysis. This report (henceforth known as "document") has been drafted by the authors concerned as a non-binding opinion on the market situation and on the instruments of investment in question and compiled by Dynamics Group in order to provide background information about the companies. It is intended exclusively for the purpose of information.

Dynamics Group has not individually verified the information and data on which this document is based. All information and data in this document originate from generally available sources which the author concerned or Dynamics Group viewed as reliable at the time of drafting this document. However, no liability can be assumed for their correctness, accuracy, completeness and appropriateness – neither expressly nor tacitly. The contents of this document do not represent an assurance or guarantee by the authors concerned or Dynamics Group. Forward-looking information or statements in this document contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations

Dynamics Group shall not be liable for any consequential damage to properties – on whatever legal grounds it may be. Liability of Dynamics Group on account of premeditation or gross negligence shall remain unaffected by this.

Dynamics Group has no permission to provide assurances or assume guarantees on behalf of the companies or a third party mentioned in this document. Neither the companies mentioned in this document nor any other individual assumes liability for any loss, damage or detriment that may result from the use of this document, especially when taking decisions on investments, or from other reasons. Dynamics Group cannot be held responsible for detrimental consequences that occur or may occur due to the use or its omission based on the views and inferences contained in this document. Past performance trends of value, price or rates do not provide any indications to the future trends for an investment. Dynamics Group does not provide any guarantees for the suggested yield or the achievement of referred targets.

This document does neither represent an offer of purchase, holding or sale of any securities, money market instruments or of derivatives, nor does it contain the basis for a contract or a commitment of any kind. Every investment, for example, in debentures, shares and options, is associated with enormous risks. A decision on investment with regard to any security may not be based on this document. This document is neither an advice on investment, nor a recommendation or invitation for purchasing, holding or selling any securities, money market instruments or derivatives.

Dynamics Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this document. However, the respective directors, employees and contractors of Dynamics Group may hold positions in the described securities and/or options, futures and other derivatives that are based on these securities.

This document has been provided to you for information only. It may not be reproduced or distributed to others or published in any other form partially or fully.

The distribution of this document and the information contained therein may be restricted in other jurisdictions by law and persons who may come into possession of this document must be aware of possible restrictions and adhere to the same. Failure to comply with such restrictions may constitute an infringement of the laws in USA or Canada governing the securities or of the laws of any other jurisdiction.

This study is protected by the copyright laws. It may be used only for the purpose as defined in this disclaimer. Portions of the study, if quoted, must be acknowledged by indicating the source. Any use other than this shall require prior written permission by Dynamics Group. Reproduction, circulation, publication and provision of online access to the document shall be regarded as its use and the same shall require permission. Circulation of this document, especially in a foreign country, may be permitted only under the provisions of the disclaimer and the applicable regulations. Unauthorized use of the study or omission of details of the source or the acknowledgement of copyright may lead to initiation of a civil suit for damages and be liable for prosecution.

If any part or individual formulations of this disclaimer are found to be unsustainable or become unsustainable at a future date, the rest of the contents and their validity shall not be affected by it.

Dynamics Group AG

Utoquai 43
CH-8008 Zürich
Tel. +41 43 268 32 32
Fax +41 43 268 32 39

Zeughausgasse 22
CH-3011 Bern
Tel. +41 31 312 28 41
Fax +41 31 312 28 49

21, rue des Caroubiers
CH-1227 Carouge/GE
Tel. +41 22 308 62 20
Fax +41 22 308 62 36

contact@dynamicsgroup.ch

www.dynamicsgroup.ch